Ligand Pharmaceuticals LGND Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's debt securities, available-for-sale, unrealized loss position, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's debt securities, available-for-sale, unrealized loss position, accumulated loss?
- Ligand Pharmaceuticals (LGND) reported debt securities, available-for-sale, unrealized loss position, accumulated loss of $800K in Q1 2026.
- How has Ligand Pharmaceuticals's debt securities, available-for-sale, unrealized loss position, accumulated loss changed year-over-year?
- Ligand Pharmaceuticals's debt securities, available-for-sale, unrealized loss position, accumulated loss increased by 3900.0% year-over-year, from $20K to $800K.